Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: A retrospective study.
Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: A retrospective study.
复制标题
DOI：
10.1111/and.13810
复制
发表时间：
2020-12
期刊：
影响因子：
2.4
通讯作者：
Takahashi S
中科院分区：
文献类型：
--
作者：
Obinata D;Suzuki S;Yamanaka Y;Yoshizawa T;Mochida J;Yamaguchi K;Takahashi S
对于使用5-α-还原酶抑制剂(5AR抑制剂)的男性，是否适当地进行前列腺活检仍不清楚，以避免不必要的活检。我们对最初PSA为4.0 ng/ml或更高的患者进行了回顾性调查，并在接受度他雄胺治疗后进行了随后的前列腺活检。自2009年9月至2018年8月，我科应用度他雄胺治疗良性前列腺增生症(BPH)399例。其中，36例治疗前PSA升高(4.0 ng/ml或以上)并随后接受前列腺活检的患者纳入本研究。我们评估了PSA动力学和变化的前列腺体积(PV)，以及前列腺癌的检测。总体而言，平均PSA在服药后6个月减少了一半。36例中有17例进行了治疗前活检，均为非恶性。治疗后15例经活检发现前列腺癌。15例中14例为临床显著癌(Gleason评分7分或以上)。Logistic回归分析发现前列腺癌的发现与PSAD、PV减少(PV前/后1)和异常MRI表现这三个变量之间存在名义上的关联。治疗前除MRI表现异常及PSAD升高外，治疗后PV降低者应考虑行前列腺活检。
Appropriate decision of prostate biopsy in men with 5α‐reductase inhibitor (5AR inhibitor) is still unclear to avoid unnecessary biopsy. We retrospectively investigated patients with initial PSA 4.0 ng/ml or more and underwent subsequent prostate biopsy following dutasteride treatment. From September 2009 to August 2018, 399 cases of benign prostate hyperplasia (BPH) were treated with dutasteride in our department. Of the total, 36 cases with elevated pre‐treatment PSA (4.0 ng/ml or more) and underwent subsequent prostate biopsy were included into this study. We evaluated PSA kinetics and changing prostate volumes (PV), and detection of prostate cancer. Overall, average PSA reduced by half at 6 months from dosing. Pre‐treatment biopsy was performed in 17 of 36 cases, and all were diagnosed as having no malignancy. After treatment, prostate cancer was detected in 15 cases by subsequent biopsy. Fourteen of 15 cases were clinically significant cancer (Gleason score 7 or more). Logistic regression analysis detected a nominal association between prostate cancer detection and three variants, PSAD, PV reduction (1–Before/After PV) and abnormal MRI findings. In addition to abnormal MRI findings and pre‐treatment of high PSAD, the case with low reduction of PV after treatment should consider performing prostate biopsy.
登录
查看更多内容
影响因子：
1.9
作者：
Serefoglu, Ege Can;Altinova, Serkan;Balbay, Derya
通讯作者：
Balbay, Derya
影响因子：
158.5
作者：
Thompson, IM;Goodman, PJ;Coltman, CA
通讯作者：
Coltman, CA
影响因子：
158.5
作者：
Andriole, Gerald L.;Bostwick, David G.;Rittmaster, Roger S.
通讯作者：
Rittmaster, Roger S.
影响因子：
5.6
作者：
Filella X;Foj L
通讯作者：
Foj L
DOI：
10.1136/bmj.k3519
发表时间：
2018-09-05
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Ilic D;Djulbegovic M;Jung JH;Hwang EC;Zhou Q;Cleves A;Agoritsas T;Dahm P
通讯作者：
Dahm P